Statistical Methods for Multi-Omics Analysis in Neurodevelopmental Disorders: From High Dimensionality to Mechanistic Insight.
This review hands BCBAs a translator for multi-omics speak so you can join biomarker projects without getting lost in jargon.
01Research in Context
What this study did
Airoldi and team wrote a plain-language guide to new statistics.
They explain tools like DIABLO and MOFA.
These tools mix gene, protein, and cell data to find shared patterns in autism, ID, and ADHD.
The paper is a roadmap, not new lab work.
What they found
The review shows three hot pathways keep popping up.
Synaptic, mitochondrial, and immune signals rise together across studies.
DIABLO and MOFA can spot these links even when each single test looks weak.
How this fits with other research
Saghazadeh et al. (2017) found higher blood BDNF in autism.
Airoldi’s review places BDNF inside the wider synaptic pathway cluster.
The older paper saw one protein; the new guide shows how to see the whole network.
Dowdy et al. (2022) warns us how to check for hidden bias in small behavior studies.
Airoldi adds that the same bias tests now exist for multi-omics data.
Together, the two papers give you a full checklist before you trust any biomarker claim.
Why it matters
You can now speak the same language as university labs.
When a parent asks about blood tests, you can explain that one marker means little but a pattern across genes, proteins, and cells can guide better goals.
Use this review to pick labs that run DIABLO or MOFA so your data joins a bigger, cleaner map.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Email your local university partner and ask if they use DIABLO or MOFA for their autism data—if yes, offer to share your ABC data for cross-checking.
02At a glance
03Original abstract
Neurodevelopmental disorders (NDDs), including autism spectrum disorder, intellectual disability, and attention-deficit/hyperactivity disorder, are genetically and phenotypically heterogeneous conditions affecting millions worldwide. High-throughput omics technologies—transcriptomics, proteomics, metabolomics, and epigenomics—offer a unique opportunity to link genetic variation to molecular and cellular mechanisms underlying these disorders. However, the high dimensionality, sparsity, batch effects, and complex covariance structures of omics data present significant statistical challenges, requiring robust normalization, batch correction, imputation, dimensionality reduction, and multivariate modeling approaches. This review provides a comprehensive overview of statistical frameworks for analyzing high-dimensional omics datasets in NDDs, including univariate and multivariate models, penalized regression, sparse canonical correlation analysis, partial least squares, and integrative multi-omics methods such as DIABLO, similarity network fusion, and MOFA. We illustrate how these approaches have revealed convergent molecular signatures—synaptic, mitochondrial, and immune dysregulation—across transcriptomic, proteomic, and metabolomic layers in human cohorts and experimental models. Finally, we discuss emerging strategies, including single-cell and spatially resolved omics, machine learning-driven integration, and longitudinal multi-modal analyses, highlighting their potential to translate complex molecular patterns into mechanistic insights, biomarkers, and therapeutic targets. Integrative multi-omics analyses, grounded in rigorous statistical methodology, are poised to advance mechanistic understanding and precision medicine in NDDs.
Biomolecules, 2025 · doi:10.3390/biom15101401